A phase I clinical and pharmacokinetic study of the new topoisomerase inhibitor GI147211 given as a 72-h continuous infusion

British Journal of Cancer

Volumn 78, Issue 10, 1998, Pages 1329-1336

  Paz Ares, L ^a   Kunka, R ^a   DeMaria, D ^a   Cassidy, J ^a   Alden, M ^a   Beranek, P ^a   Kaye, S ^a   Littlefield, D ^a   Reilly, D ^a   Depee, S ^a   Wissel, P ^a   Twelves, C ^a   O'Dwyer, P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Camptothecin analogues; Continuous infusion; GG211; GI147211; Pharmacodynamics; Pharmacokinetics; Phase I trial; Topoisomerase I inhibitor

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; GLUCOSE; LACTONE DERIVATIVE; LURTOTECAN; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONTINUOUS INFUSION; DOSE CALCULATION; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG URINE LEVEL; FATIGUE; FEMALE; HEADACHE; HUMAN; LIVER CELL CARCINOMA; MALE; MAXIMUM PERMISSIBLE DOSE; NAUSEA; NEUTROPENIA; OVARY CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0031789627     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.679     Document Type: Article

References (29)